Dr. Nina Hanke

Forschungsgebiet

Physiologie-basierte Pharmakokinetik (PBPK) Modellierung von Arzneistoff-Wechselwirkungen

Lebenslauf

Seit 06/2014: Postdoktorandin Klinische Pharmazie, Universität des Saarlandes

09/2011 – 05/2014: Laboratory Head Biochemistry, ElexoPharm GmbH

02/2010 – 08/2011: Scientific Expert In Vitro Pharmacology, Abbott Products GmbH

06/2005 – 01/2010: Postdoktorandin Humanphysiologie, Medizinische Hochschule Hannover

10/2001 – 06/2005: Promotion Humanphysiologie, Medizinische Hochschule Hannover

10/1996 – 10/2001: Studium Biochemie, Leibniz Universität Hannover

06/1996: Abitur, Ricarda-Huch-Gymnasium Hannover

Publikationen

Vorträge 

Hanke N. Physiologically-based pharmacokinetic (PBPK) modeling of the chemotherapeutic zoptarelin doxorubicin and model application for drug-drug interaction (DDI) potential analysis. CESAR Annual Meeting 2018, Berlin, Germany.

Hanke N. Physiologically-based pharmacokinetic modeling of drug-drug interactions: rifampin, midazolam and digoxin. 7th International DDI Workshop 2016, Marbach Castle, Germany.

 

Manuskripte

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients. Pharmaceutics 2019, 11(4), 152.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T. PBPK models for CYP1A2 DDI prediction: a modelling network of fluvoxamine, theophylline, caffeine, rifampicin and midazolam. CPT Pharmacometrics Syst Pharmacol 2019;Epub:10.1002/psp4.12397.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7(10):647-659.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC. Population nutrikinetics of green tea extract. PLoS One 2018;13(2):e0193074.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis. Cancer Chemother Pharmacol 2018;81(2):291-304.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T. Clarithromycin, Midazolam, and Digoxin: Application of PBPK modeling to gain new insights into drug-drug interactions and co-medication regimens. AAPS J 2017;19(1):298-312.


Kontakt

Dr. Nina Hanke

Klinische Pharmazie

Universität des Saarlandes

Campus C2 2, Zimmer 0.11

66123 Saarbrücken 

 

T: +49/681/302-2484

F: +49/681/302-70258

n.hanke[at]mx.uni-saarland.de